en Cardiovascular Cardiovascular Original Research: Clinical Science Original Research: Clinical Science <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-style:italic"><b><span style="font-size:9.0pt"><span style="font-style:normal">Background: </span></span></b><span style="font-size:9.0pt"><span style="font-style:normal">Coronary slow flow syndrome or phenomenon (CSFP) is a coronary artery disease that may cause cardiac ischemia, symptoms, and related complications. This study, conducted as a randomized controlled trial, assessed and compared the effects of a treatment plan comprising aspirin, statin, nitrate, and Nicorandil on the quality of life of patients with CSFP.</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-style:italic"><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; <b>Methods:</b> Out of 963 patients who underwent coronary angiography at Booalisina University Hospital in Qazvin, 52 individuals diagnosed with primary CSFP were enrolled in the study. They were randomly divided into two groups, with one receiving a three-drug treatment with 80 mg of aspirin, 20 mg of atorvastatin daily, and 2.6 mg of nitroglycerin every 12 hours (26 patients) and in the second group plus nicorandil 10 mg every 12 hours (26 patients). After two months, the patient&#39;s QOL was evaluated and compared using McNew&#39;s quality of life questionnaire. The SPSS version 16 software was used for data analysis.</span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-style:italic"><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; <b>Results:</b> In both groups, after two months, the QOL scores in physical, emotional, social, and overall (</span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal"><0.001) were significantly improved compared to the baseline (before the treatment).&nbsp; The comparison between the two groups revealed no statistically significant differences in emotional, social, or overall quality of life scores, but the physical dimension of the quality of life in the group who received nicorandil showed more improvement than the other group (</span></span><span style="font-size:9.0pt">P</span><span style="font-size:9.0pt"><span style="font-style:normal">=0.032). </span></span></span></span></span></span></span></span><br> <span style="font-size:13pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="text-autospace:none"><span style="font-family:&quot;Times New Roman&quot;,serif"><span style="font-style:italic"><span style="font-size:9.0pt"><span style="font-style:normal">&nbsp;&nbsp; <b>Conclusion:</b> A combination therapy of aspirin, atorvastatin, and nitrates has been demonstrated to significantly improve the quality of life in patients with Coronary Slow Flow Phenomenon (CSFP). However, the addition of nicorandil to this regimen does not provide significant further improvement, according to present findings. </span></span></span></span></span></span></span></span><br> &nbsp; Slow coronary blood flow syndrome, Quality of life, Statin, Nitrate, Aspirin, Nicorandil 700 706 http://mjiri.iums.ac.ir/browse.php?a_code=A-10-9123-1&slc_lang=en&sid=1 Majid Haji Karimi majidhajikarimi57@gmail.com 200319475328460092102 200319475328460092102 No Clinical Research Development Unit, Booalisina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran Behrouz Bokani Behroozboukani@gmail.com 200319475328460092103 0009-0004-1035-1178 No Cardiovascular Department, Booalisina Hospital , Qazvin University of Medical Sciences, Qazvin, Iran Amir Javadi Javadi_a@yahoo.com 200319475328460092104 200319475328460092104 No Department of Community Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran Zohreh Yazdi dr.zyazdi@yahoo.com 200319475328460092105 200319475328460092105 No Department of Community Medicine, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran Hamid Reza Javadi hrjavadi@qums.ac.ir 200319475328460092106 200319475328460092106 Yes Clinical Research Development Unit, Booalisina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran